Entrust Clinical Research LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$493,929	34
2024	Research	$1,257,477	59
2023	Research	$389,688	17
2022	Research	$2,427,197	23
2021	Research	$1,188,045	23

Breakdown

Who paid Research payments · program years 2021–2025

Pfizer Inc. $5,217,074 90 payments
Currax Pharmaceuticals LLC $404,058 20 payments
Bausch Health US, LLC $77,648 40 payments
Sage Therapeutics, Inc. $33,105 3 payments
Chiesi USA, Inc. $24,451 3 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $2,883,763 23 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $884,154 17 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $606,345 13 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $477,868 12 payments
NB (Contrave) Cardiovascular Outcomes Trial $404,058 20 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $253,611 11 payments
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis $77,648 40 payments
A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $54,831 8 payments
An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 2Arm Study to Investigate A Repeat 5Day Course of Nirmatrelvirritonavir Compared to Placeboritonavir in Participants at Least 12 Years of Age With Rebound of Covid19 Symptoms and Rapid Antigen Test Positivity $38,840 5 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $24,451 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.